Studies by Kiel, Holst and Deacon uncovered that GLP-1 is rapidly degraded by an enzyme called DPP-4
R., Holscher, C
Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, doubleblind, placebo and activecontrolled, parallelgroup, phase 2 trial conducted in the USA
-1.86% A1c reduction on the highest dose of semaglutide after 40 weeks
GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized weight loss and diabetes care
In the phase 2b trial, however, the reductions in glycated hemoglobin and body weight in participants treated with NNC0090-2746 were similar to those in the group treated with liraglutide (76), and no phase 3 trial of NNC0090-2746 has been reported yet